Literature DB >> 23771321

Effectiveness of intratympanic dexamethasone for refractory sudden sensorineural hearing loss.

Omer Erdur1, Fatma Tulin Kayhan, Ahmet Adnan Cirik.   

Abstract

The purpose of this study was to investigate the effectiveness of intratympanic steroids in patients with idiopathic sudden sensorineural hearing loss who did not respond to initial systemic steroid therapy. This retrospective study involved 51 patients, who did not respond to systemic steroids as a first-line treatment. Initial systemic steroid therapy consisted of administration of methylprednisolon intravenously (250 mg) at the first day and followed by orally (1 mg/kg) tapering for 14 days. Twenty-one patients accepted intratympanic treatment, and the remaining 30 patients who refused intratympanic treatment were evaluated as the control group. Steroids (dexamethasone drops, 1 mg/mL) were administered through a ventilation tube. Hearing was assessed immediately before treatment and 2 months after treatment. Recovery of hearing was defined as an improvement of >20 dB in the pure tone average. We tested 250, 500, 1,000, 2,000, 4,000, and 8,000 Hz frequencies for the pure tone audiometric evaluation. Statistically Student's t test, Mann-Whitney U test, Chi-squared and Fisher's exact tests were used. The pure tone average improved in 47.6% of the intratympanic group and in 10% of the control group (p = 0.002), with pure tone average improvements of 19.9 ± 16.5 and 4.76 ± 9.6 dB in the intratympanic and control groups, respectively. When the hearing threshold at each frequency was analyzed, improvements at all frequencies were significantly greater in the intratympanic steroid group when compared with the control group (p < 0.01). Intratympanic steroid administration is an effective therapy for sudden sensorineural hearing loss in patients, who are refractory to primary systemic steroid therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23771321     DOI: 10.1007/s00405-013-2594-x

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  28 in total

1.  Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss.

Authors:  Yun-Hoon Choung; Keehyun Park; You Ree Shin; Min Jung Cho
Journal:  Laryngoscope       Date:  2006-05       Impact factor: 3.325

Review 2.  Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.

Authors:  David S Haynes; Matthew O'Malley; Seth Cohen; Kenneth Watford; Robert F Labadie
Journal:  Laryngoscope       Date:  2007-01       Impact factor: 3.325

3.  The nature and progression of injury in the organ of Corti during ischemia.

Authors:  T E Billett; P R Thorne; J B Gavin
Journal:  Hear Res       Date:  1989-09       Impact factor: 3.208

4.  Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation.

Authors:  S S Chandrasekhar
Journal:  Otol Neurotol       Date:  2001-01       Impact factor: 2.311

5.  The pathology of sudden deafness.

Authors:  H F Schuknecht; R S Kimura; P M Naufal
Journal:  Acta Otolaryngol       Date:  1973 Aug-Sep       Impact factor: 1.494

6.  Comparison of intratympanic and intravenous dexamethasone treatment on sudden sensorineural hearing loss with diabetes.

Authors:  Seiji Kakehata; Akira Sasaki; Kasumi Oji; Kazunori Futai; Shuji Ota; Kimitoshi Makinae; Hideichi Shinkawa
Journal:  Otol Neurotol       Date:  2006-08       Impact factor: 2.311

7.  Quantification of solute entry into cochlear perilymph through the round window membrane.

Authors:  A N Salt; Y Ma
Journal:  Hear Res       Date:  2001-04       Impact factor: 3.208

8.  Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy.

Authors:  Stefan K Plontke; Hubert Löwenheim; Jürgen Mertens; Corinna Engel; Christoph Meisner; Andy Weidner; Rainer Zimmermann; Serena Preyer; Assen Koitschev; Hans-Peter Zenner
Journal:  Laryngoscope       Date:  2009-02       Impact factor: 3.325

9.  Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy.

Authors:  Haralampos Gouveris; Oksana Selivanova; Wolf Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-04-29       Impact factor: 2.503

10.  Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment.

Authors:  Ho Guan-Min Ho; Hung-Ching Lin; Min-Tsan Shu; Cheng-Chien Yang; Hsun-Tien Tsai
Journal:  Laryngoscope       Date:  2004-07       Impact factor: 3.325

View more
  8 in total

1.  [Intratympanic injection therapy for therapy refractory acute hearing loss: A safe option for secondary treatment].

Authors:  G Mühlmeier; S Maier; M Maier; H Maier
Journal:  HNO       Date:  2015-10       Impact factor: 1.284

2.  Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss: a meta-analysis.

Authors:  Yang Gao; Dong Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-12       Impact factor: 2.503

Review 3.  Research progress in refractory sudden hearing loss: steroid therapy.

Authors:  Ya Liu; Qiongqiong Chen; Yaping Xu
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

4.  Idiopathic sudden sensorineural hearing loss: Effectiveness of salvage treatment with low-dose intratympanic dexamethasone.

Authors:  Pedro Salvador; Francisco Moreira da Silva; Rui Fonseca
Journal:  J Otol       Date:  2020-07-02

5.  Intratympanic corticosteroid as salvage therapy in treatment of idiopathic sudden sensorineural hearing loss: A systematic review and meta-analysis.

Authors:  Louise Devantier; Henriette Edemann Callesen; Lasse Rehné Jensen; Christian Mirian; Therese Ovesen
Journal:  Heliyon       Date:  2022-02-15

6.  Local inner ear application of dexamethasone in cochlear implant models is safe for auditory neurons and increases the neuroprotective effect of chronic electrical stimulation.

Authors:  Verena Scheper; Roland Hessler; Mareike Hütten; Maciej Wilk; Claude Jolly; Thomas Lenarz; Gerrit Paasche
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240

7.  Dexamethasone for Inner Ear Therapy: Biocompatibility and Bio-Efficacy of Different Dexamethasone Formulations In Vitro.

Authors:  Ziwen Gao; Jana Schwieger; Farnaz Matin-Mann; Peter Behrens; Thomas Lenarz; Verena Scheper
Journal:  Biomolecules       Date:  2021-12-17

8.  Intratympanic steroid injection and hyperbaric oxygen therapy for the treatment of refractory sudden hearing loss.

Authors:  Filiz Gülüstan; Zahide Mine Yazıcı; Wesam M E Alakhras; Omer Erdur; Harun Acipayam; Levent Kufeciler; Fatma Tulin Kayhan
Journal:  Braz J Otorhinolaryngol       Date:  2016-11-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.